CD19 and acute lymphoblastic leukemia: Specifically, 8 samples of B‐ALL were post single Blinatumomab therapy and serially derived from the same patient, of which 5 samples were positive for refractory disease by both FC (bright CD19 antigen) and CD19S FISH, including the first sample in the series (8 days post‐application).